Chongqing Pharscin Pharmaceutical Co Ltd

Chongqing Pharscin Pharmaceutical Co., Ltd. announced that its Ethylenediamine Diaceturate for Injection, in 0.2 gram and 0.4 gram strengths, has received a drug re-registration approval notice issued by the Chongqing Medical Products Administration. The approval number is valid until February 20, 2032, and the drug has a shelf life of 24 months. The product is indicated for the prevention and treatment of bleeding from various causes. Because it has not been produced for a long time, the company must apply to the municipal drug regulatory authority and pass on-site inspection and sampling tests before it can be marketed and sold. The company stated that this re-registration will ensure normal production and sales of the drug and will not have a significant impact on operating performance in the short term.

Huasen Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 62.98 million yuan, an increase of 9.03 million yuan compared with the same period last year, up 16.74% year-on-year, achieving three consecutive years of growth. The company's total operating revenue was 414 million yuan, a decrease of 28.36 million yuan from the same period last year, down 6.42% year-on-year. Net cash inflow from operating activities was 54.66 million yuan, up 98.58% year-on-year. The company's latest asset-liability ratio was 14.77%, gross margin was 59.26%, ROE was 3.62%, and diluted earnings per share was 0.15 yuan.

Chengdu Huasen Aorui Pharmaceutical Co., Ltd., a controlling subsidiary of Chongqing Huasen Pharmaceutical Co., Ltd., has received a drug clinical trial approval notice issued by the National Medical Products Administration for its Class 1.1 new drug ORIC-1327 phosphate eye drops, agreeing to the commencement of clinical trials. The product has been approved in six specifications, with indications for glaucoma and ocular hypertension. It is a selective small molecule inhibitor independently developed by Huasen Aorui with fully owned intellectual property rights. Preclinical studies have demonstrated significant intraocular pressure-lowering effects and good ocular safety in New Zealand rabbits and cynomolgus monkeys. This is the second Class 1.1 new drug project of Huasen Aorui to receive clinical approval. To date, Huasen Aorui and Chongqing Huasen Yingnuo Biotechnology Co., Ltd. have collectively obtained clinical trial approvals for three Class 1.1 new drug projects. The company cautions that drug development from clinical trials to approved production is affected by multiple factors, and there is uncertainty in the progress and research results, with no guarantee that the product will ultimately be approved for market launch.

Chongqing Huasen Pharmaceutical Co., Ltd. announced that its product Penehyclidine Hydrochloride Injection has been proposed for selection in the 12th National Drug Centralized Procurement, with a specification of 1ml:1mg and a proposed selection price of 3.57 yuan per unit. The procurement period runs from the implementation date of the selection results until December 31, 2029. This product is a selective anticholinergic drug, primarily used for pre-anesthetic medication and emergency treatment of organophosphate poisoning. It is an integrated API and formulation product of the company, which passed the consistency evaluation in January 2024. Data from Yaozhiwang shows that hospital-end sales in 2025 remained stable at 602 million yuan. The company stated that this proposed selection is conducive to enhancing brand influence and will have a positive impact on future development. However, the procurement agreement has not yet been signed, and there are still uncertainties in subsequent matters.

Chongqing Huasen Pharmaceutical announced that five of its products have been newly included in the National Essential Medicines List 2026 Edition issued by the National Health Commission. The newly selected varieties include Duliang Soft Capsules, Ganju Bingmei Tablets, Terazosin, Cilostazol, and Acyclovir for Injection. The list will take effect from September 1, 2026. Among the specifications previously included in the 2018 Essential Medicines List, only Isoniazid Tablets have been removed this time, while all other specifications remain. The company stated that inclusion in the Essential Medicines List will help further expand the primary healthcare market, increase market share, and have a positive impact on long-term development, but the specific short-term impact on performance cannot yet be determined.